Smith Brilee M, Giddens Michelle M, Neil Jessica, Owino Sharon, Nguyen TrangKimberly T, Duong Duc, Li Fengqiao, Hall Randy A
Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA.
Neurorepair Therapeutics, Inc., Research Triangle Park, NC, USA.
Neuroscience. 2017 Sep 1;358:49-57. doi: 10.1016/j.neuroscience.2017.06.006. Epub 2017 Jun 20.
GPR37 is an orphan G protein-coupled receptor that is predominantly expressed in the brain and found at particularly high levels in oligodendrocytes. GPR37 has been shown to exert effects on oligodendrocyte differentiation and myelination during development, but the molecular basis of these actions is incompletely understood and moreover nothing is known about the potential role(s) of this receptor under demyelinating conditions. To shed light on the fundamental biology of GPR37, we performed proteomic studies comparing protein expression levels in the brains of mice lacking GPR37 and its close relative GPR37-like 1 (GPR37L1). These studies revealed that one of the proteins most sharply decreased in the brains of Gpr37/Gpr37L1 double knockout mice is the myelin-associated glycoprotein MAG. Follow-up Western blot studies confirmed this finding and demonstrated that genetic deletion of Gpr37, but not Gpr37L1, results in strikingly decreased brain expression of MAG. Further in vitro studies demonstrated that GPR37 and MAG form a complex when expressed together in cells. As loss of MAG has previously been shown to result in increased susceptibility to brain insults, we additionally assessed Gpr37-knockout (Gpr37) vs. wild-type mice in the cuprizone model of demyelination. These studies revealed that Gpr37 mice exhibit dramatically increased loss of myelin in response to cuprizone, yet do not show any increased loss of oligodendrocyte precursor cells or mature oligodendrocytes. These findings reveal that loss of GPR37 alters oligodendrocyte physiology and increases susceptibility to demyelination, indicating that GPR37 could be a potential drug target for the treatment of demyelinating diseases such as multiple sclerosis.
GPR37是一种孤儿G蛋白偶联受体,主要在大脑中表达,在少突胶质细胞中含量特别高。已证明GPR37在发育过程中对少突胶质细胞分化和髓鞘形成有影响,但这些作用的分子基础尚不完全清楚,而且对于该受体在脱髓鞘条件下的潜在作用也一无所知。为了阐明GPR37的基础生物学特性,我们进行了蛋白质组学研究,比较了缺乏GPR37及其近亲GPR37样1(GPR37L1)的小鼠大脑中的蛋白质表达水平。这些研究表明,在Gpr37/Gpr37L1双敲除小鼠大脑中急剧减少的一种蛋白质是髓鞘相关糖蛋白MAG。后续的蛋白质印迹研究证实了这一发现,并表明Gpr37基因缺失而非Gpr37L1基因缺失会导致大脑中MAG表达显著降低。进一步的体外研究表明,GPR37和MAG在细胞中共同表达时会形成复合物。由于先前已证明MAG缺失会导致对脑损伤的易感性增加,我们还在铜螯合剂诱导的脱髓鞘模型中评估了Gpr37基因敲除(Gpr37)小鼠与野生型小鼠。这些研究表明,Gpr37小鼠对铜螯合剂诱导的脱髓鞘反应中髓鞘损失显著增加,但少突胶质前体细胞或成熟少突胶质细胞的损失并未增加。这些发现揭示了GPR37缺失会改变少突胶质细胞生理学并增加对脱髓鞘的易感性,表明GPR37可能是治疗多发性硬化症等脱髓鞘疾病的潜在药物靶点。